Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

A spokesperson confirmed the Danish drugmaker has asked U.S. regulators to clear an oral version of its weight loss drug ...

Novo Nordisk filed for approval of an oral, 25-mg formulation of semaglutide “earlier this year,” according to a company spokesperson.

Novo Nordisk stock popped Tuesday on reports it's asked the FDA to approve its weight-loss pill, an oral version of Wegovy.

Novo Nordisk has signed an exclusive global licensing deal worth up to $2 billion for UBT251, a weight-loss drug developed by China-based The United Laboratories International Holdings Limited.

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

The tortoise (Eli Lilly) has caught the hare (Novo Nordisk), according to a report from BMO Capital Markets, which cites the ...

which was a significant improvement on Novo Nordisk's main marketed obesity drug – Wegovy – which is based on semaglutide alone. Novo Nordisk emphasised an interpretation of the data ...

The request reportedly came two years after a Phase 3 study of Rybelsus, an oral formulation of semaglutide, which showed ...

Texas-based Lexicon has been studying LX9851 as a standalone therapy and in combination with GLP-1 agonists such as semaglutide, the main ingredient in Novo Nordisk’s Wegovy. At the Obesity Week ...

However, Novo Nordisk is making good progress with its pipeline, which includes several other new candidates for T2D and obesity ... underscored by its marketed semaglutide (GLP-1 agonist ...

Novo Nordisk is actively exploring additional uses for semaglutide, including evaluating Wegovy for heart failure in diabetes and obesity patients and Ozempic as a treatment for T2D and chronic ...